Company Overview - ESSA Pharma is focused on developing novel therapies for prostate and other androgen-driven cancers[7] - The company's lead candidate, EPI-7386, is a first-in-class oral, small molecule androgen receptor N-terminal domain inhibitor ("Aniten")[9, 28] - As of March 31, 2023, ESSA had $157 million in cash and short-term deposits, providing a runway through 2025[9, 69] EPI-7386 Monotherapy Development - Phase 1a study showed EPI-7386 was safe and well-tolerated, with tumor volume decreases observed in some patients[38] - ctDNA declines were observed in patients with AR mutations, amplifications, and truncations, suggesting activity against these tumors[38] - Phase 1b expansion study is underway to verify the recommended Phase 2 dose and gain further insight into EPI-7386's biological activity[40, 41] EPI-7386 Combination Therapy Development - ESSA is collaborating with multiple companies to evaluate EPI-7386 in combination with second-generation antiandrogens like enzalutamide, apalutamide, and darolutamide[49] - Initial data from the Phase 1/2 EPI-7386 + enzalutamide combination study showed rapid, deep, and durable PSA reductions[58] - In the combination study, 5 out of 6 patients achieved a PSA90, and 4 out of 6 patients achieved a PSA90 in 90 days and ultimately achieved a PSA < 02 ng/mL[58] Market and Opportunity - Prostate cancer is the 2nd most common cause of male cancer deaths, with an estimated 268,000 new cases and 34,500 deaths in 2022 in America[19] - Global sales of leading antiandrogens generated over $86 billion in 2021[19]

Exhibit 99.1 ESSA Pharma Reports Financial Results for Fiscal Second Quarter Ended March 31, 2025 Company continues to explore and review strategic options focused on maximizing shareholder value SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, May 8, 2025 - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX), a pharmaceutical company that, prior to the discontinuation of its clinical trials and development programs, had been focused on developing novel therapies for the treatment of prostate c ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37410 ESSA Pharma Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 98-125 ...

LOS ANGELES, March 19, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ESSA Pharma Inc. ("ESSA" or "the Company") (NASDAQ: EPIX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between December 12, 2023 and October 31, 2024, inclusive (the "Class Period"), a ...

NEW YORK, March 13, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ESSA Pharma Inc. (NASDAQ: EPIX) between December 12, 2023 and October 31, 2024, both dates inclusive (the "Class Period"), of the important March 25, 2025 lead plaintiff deadline.So what: If you purchased ESSA Pharma securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.Wh ...

Core Viewpoint - A class action has been filed against ESSA Pharma Inc. for allegedly misleading investors about the efficacy of its drug candidate masofaniten, particularly in its combination with enzalutamide for treating prostate cancer [1][2]. Company Overview - ESSA Pharma Inc. is a clinical stage pharmaceutical company focused on developing small molecule drugs for prostate cancer treatment [1]. - The lead product candidate is masofaniten, which was being tested in combination with enzalutamide in a clinical trial for metastatic castration-resistant prostate cancer (CRPC) [1]. Allegations - The complaint alleges that ESSA failed to disclose that: - Masofaniten combined with enzalutamide showed no clear efficacy benefit over enzalutamide alone [2]. - The combination was less effective in treating prostate cancer than previously indicated [2]. - The M-E Combination Study was unlikely to meet its prespecified Phase 2 primary endpoint [2]. - The company overstated masofaniten's clinical, regulatory, and commercial prospects [2]. Recent Developments - On October 31, 2024, ESSA announced the termination of Phase 2 of the M-E Combination Study, citing an interim review that indicated a higher rate of PSA90 response in patients treated with enzalutamide alone compared to the combination [3]. - The company noted that a futility analysis showed a low likelihood of meeting the study's primary endpoint and planned to terminate other clinical studies involving masofaniten [3]. - Following this announcement, ESSA's stock price dropped by $3.80 per share, or 73.08%, closing at $1.40 per share on November 1, 2024 [3].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of ESSA Pharma Inc. regarding a class action lawsuit due to alleged misleading statements related to the efficacy of masofaniten in combination with enzalutamide for prostate cancer treatment [1][2]. Group 1: Allegations and Class Period - The class period for the allegations is from December 12, 2023, to October 31, 2024 [2]. - Allegations include that the defendants made materially false statements about masofaniten's efficacy, claiming it had benefits over enzalutamide alone, which was not supported by evidence [2]. - The M-E Combination Study was unlikely to meet its primary endpoint, contradicting the defendants' claims about masofaniten's prospects [2]. Group 2: Next Steps for Shareholders - Shareholders are encouraged to register for the class action by March 25, 2025, to potentially become lead plaintiffs [3]. - Registered shareholders will receive updates through a portfolio monitoring software regarding the case's progress [3]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit and fraud, ensuring companies adhere to responsible business practices [4]. - The firm seeks recovery for investors who suffered losses due to misleading statements that inflated stock prices [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of ESSA Pharma Inc. regarding a class action lawsuit due to alleged misleading statements related to the efficacy of masofaniten in combination with enzalutamide for prostate cancer treatment [1][2]. Group 1: Allegations - The complaint alleges that during the class period from December 12, 2023, to October 31, 2024, the defendants made materially false and misleading statements about masofaniten's efficacy [2]. - It is claimed that masofaniten in combination with enzalutamide did not demonstrate a clear efficacy benefit over enzalutamide alone, contrary to what was communicated to investors [2]. - The M-E Combination Study was unlikely to meet its prespecified Phase 2 primary endpoint, indicating that the clinical and commercial prospects of masofaniten were overstated [2]. Group 2: Class Action Details - The deadline for shareholders to register for the class action is March 25, 2025, and they are encouraged to register without delay [3]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the status of the case [3]. - There is no cost or obligation for shareholders to participate in this class action [3]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit and fraud [4]. - The firm aims to ensure that companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of ESSA Pharma Inc. regarding a class action lawsuit due to alleged misleading statements related to the efficacy of masofaniten in combination with enzalutamide for prostate cancer treatment [1][3]. Summary by Relevant Sections Class Period and Allegations - The class period for the lawsuit is from December 12, 2023, to October 31, 2024 [3]. - Allegations include that the defendants made materially false and misleading statements about masofaniten's efficacy, claiming it had no clear benefit over enzalutamide alone [3]. - It is asserted that the M-E Combination Study was unlikely to meet its primary endpoint, leading to overstated clinical and commercial prospects for masofaniten [3]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by March 25, 2025, to potentially become lead plaintiffs [4]. - Registration will provide shareholders with updates throughout the case lifecycle, and participation incurs no cost or obligation [4]. Law Firm's Commitment - The Gross Law Firm aims to protect investors' rights against deceit and fraud, emphasizing responsible business practices [5].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of ESSA Pharma Inc. regarding a class action lawsuit due to alleged misleading statements related to the efficacy of masofaniten in combination with enzalutamide for prostate cancer treatment [1][2]. Group 1: Allegations - The complaint alleges that during the class period from December 12, 2023, to October 31, 2024, the defendants made materially false and misleading statements about masofaniten's efficacy [2]. - It is claimed that masofaniten in combination with enzalutamide did not demonstrate a clear efficacy benefit over enzalutamide alone, contrary to what was communicated to investors [2]. - The M-E Combination Study was unlikely to meet its prespecified Phase 2 primary endpoint, indicating that the clinical and commercial prospects of masofaniten were overstated [2]. Group 2: Class Action Details - The deadline for shareholders to register for the class action is March 25, 2025, and they are encouraged to register without delay [3]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates on the case's status [3]. - There is no cost or obligation for shareholders to participate in the case [3]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect the rights of investors who have suffered losses due to deceit and illegal business practices [4]. - The firm is committed to ensuring companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements [4].